Abstract:While platelets play a vital role in preventing excessive bleeding after injury (hemostasis), they also contribute to the genesis of thrombotic disorders. On this basis, research efforts have focused on identifying new targets and/or designing agents against these targets for therapeutic purposes. The P2Y 12 receptor (P2Y 12 R) remains one of the most attractive antiplatelet targets given that it plays a central role in platelet function. Furthermore, clopidogrel (Plavix®), which is a P2Y 12 R antagonist, is one of the most commonly prescribed drugs. However, one of the limitations facing antiplatelet therapeutic strategies is the lack of safe and/or suitable parenteral antiplatelet agents or formulations in order to complement oral agents. Based on these considerations, we designed and characterized the biological activity of a liposomal formulation (i.e., soya phosphatidylcholine, 50 mg; and cholesterol, 5 mg) of clopidogrel bisulfate under ex vivo and in vivo experimental settings. The liposomal clopidogrel was then administered by intravenous route (IV) to C57BL/6 mice through their tail vein, and our results revealed that one (1) hour post injection this formulation relative to vehicle control: 1. has the capacity to dose dependently (2 or 6 mg/kg) inhibit platelet aggregation induced by the agonist ADP; 2. this inhibitory effect was found to be selective given that it produced no detectable effects on aggregation mediated by a non‐ADP dependent pathway (i.e., the thromboxane receptor pathway stimulated by the agonist U46619); 3. prolong the tail bleeding time (modulate hemostasis), again in a dose‐dependent manner; and 4. confer protection (at 6 mg/kg) against the development of occlusive events using a carotid artery FeCl 3 injury‐induced thrombosis model. Collectively, we have successfully prepared and characterized a novel IV formulation for clopidogrel; which exhibits pharmacological activity on mouse platelets, at least 1 hour post administration, and under in vivo conditions. This formulation is expected to have a wide‐therapeutic application, given the limitations of the only currently available IV antiplatelet therapeutic agents (i.e., the platelet glycoprotein IIb IIIa antagonists). Support or Funding Information College of Pharmacy (to F.T.K), Western University of Health Sciences, Pomona, CA 91766

BF066, a novel dual target antiplatelet agent without significant bleeding.

BF061, a Novel Antiplatelet and Antithrombotic Agent Targeting P2Y12 Receptor and Phosphodiesterase

BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.

Preparation and Characterization of Solid Dispersion of Novel Dual Antiplatelet Agent BF061 for Oral Use

Tools and DRugs BF 0801 , a novel adenine derivative , inhibits platelet activation via phosphodiesterase inhibition and P 2 Y 12 antagonism

Antimicrobial Peptide Cathelicidin-BF Inhibits Platelet Aggregation by Blocking Protease-Activated Receptor 4

Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that

Np-184[2-(5-Methyl-2-Furyl) Benzimidazole], A Novel Orally Active Antithrombotic Agent with Dual Antiplatelet and Anticoagulant Activities

Antiplatelet Effects of Selected Xanthine-Based Adenosine A2A and A2B Receptor Antagonists Determined in Rat Blood

Synthesis and Biological Evaluation of N-Butylphthalide Derivatives As Anti-Platelet Aggregation Agents

Optimization of P2Y12 Antagonist Ethyl 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties

In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets

Synthesis and biological evaluation of N 6 derivatives of 8-azapurine as novel antiplatelet agents

A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y 12 Receptor

Study on Antiplatelet Effect of a New Thiophenopyridine Platelets P2Y12 Receptor Antagonist DV-127.

Synthesis and Biological Evaluation of BMS-986120 and Its Deuterated Derivatives As PAR4 Antagonists.

A Novel Parenteral Formulation For the Antiplatelet Agent Clopidogrel

Synthesis and Biological Evaluation of N6 Derivatives of 8-Azapurine As Novel Antiplatelet Agents

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin Αiibβ3.